Institution · EuroEspes Biomedical Research Center
Most cited papers from EuroEspes Biomedical Research Center
What are the most cited papers from EuroEspes Biomedical Research Center?
The most cited paper from EuroEspes Biomedical Research Center is "Parkinson’s Disease: From Pathogenesis to Pharmacogenomics" (Ramón Cacabelos, 2017), with 564 citations. Next come "Celastrol, a potent antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer's disease" (375) and "Serum TNF-alpha levels are increased and correlate negatively with free IGF-I in Alzheimer disease" (281).
Showing 50 of 61 papers. Every paper with more than 42 citations is listed.
| # | Paper | ||
|---|---|---|---|
| 1 | Parkinson’s Disease: From Pathogenesis to Pharmacogenomics Ramón Cacabelos · International Journal of Molecular Sciences | 4 Mar 2017 | 564 |
| 2 | Celastrol, a potent antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer's disease ANTHONY C. ALLISON, Ramón Cacabelos, Valter Lombardi et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry | Oct 2001 | 375 |
| 3 | Serum TNF-alpha levels are increased and correlate negatively with free IGF-I in Alzheimer disease Antón Álvarez, Ramón Cacabelos, Carolina Sanpedro et al. · Neurobiology of Aging | 30 Mar 2006 | 281 |
| 4 | Neuroprotection by memantine against neurodegeneration induced by β-amyloid(1–40) José Javier Miguel-Hidalgo, X. Anton Alvarez, Ramón Cacabelos et al. · Brain Research | Dec 2002 | 265 |
| 5 | Characterization of cytokine production, screening of lymphocyte subset patterns and in vitro apoptosis in healthy and Alzheimer's Disease (AD) individuals Valter Lombardi, Magdalena Garcı́a, Luis Carlos Rey et al. · Journal of Neuroimmunology | Jun 1999 | 181 |
| 6 | Resting-State Network Disruption and APOE Genotype in Alzheimer's Disease: A lagged Functional Connectivity Study Leonides Canuet, Iván Tellado, Verónica Couceiro et al. · PLoS ONE | 25 Sep 2012 | 165 |
| 7 | Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics. Ramón Cacabelos · PubMed | Jun 2007 | 164 |
| 8 | Novel tacrine-related drugs as potential candidates for the treatment of Alzheimer’s disease Alejandro Romero, Ramón Cacabelos, María Jesús Oset‐Gasque et al. · Bioorganic & Medicinal Chemistry Letters | 18 Feb 2013 | 157 |
| 9 | The glutamatergic system and neurodegeneration in dementia: preventive strategies in Alzheimer's disease Ramón Cacabelos, Masatoshi Takeda, Bengt G. Winblad · International Journal of Geriatric Psychiatry | 1999 | 155 |
| 10 | Epigenetics of Aging and Alzheimer’s Disease: Implications for Pharmacogenomics and Drug Response Ramón Cacabelos, Clara Torrellas · International Journal of Molecular Sciences | 21 Dec 2015 | 143 |
| 11 | Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion X. Anton Alvarez, Ricardo Mouzo, Victor Pichel et al. · Methods and Findings in Experimental and Clinical Pharmacology | 1999 | 140 |
| 12 | Blood levels of histamine, IL-1β, and TNF-α in patients with mild to moderate alzheimer disease X. Anton Alvarez, Andrés Franco, L. Fernández‐Novoa et al. · Molecular and Chemical Neuropathology | Oct 1996 | 139 |
| 13 | Molecular genetics of Alzheimer's disease and aging. Ramón Cacabelos, L. Fernández‐Novoa, Valter Lombardi et al. · PubMed | Jul 2005 | 119 |
| 14 | The role of pharmacogenomics in adverse drug reactions Ramón Cacabelos, Natalia Cacabelos, Juan C. Carril · Expert Review of Clinical Pharmacology | 27 Mar 2019 | 116 |
| 15 | Pharmacogenomics in Alzheimer's Disease Ramón Cacabelos · Methods in molecular biology | 2008 | 110 |
| 16 | A 24‐week, double‐blind, placebo‐controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease X. Anton Alvarez, R Cacabelos, Marta Laredo et al. · European Journal of Neurology | 2006 | 98 |
| 17 | Histamine function in brain disorders L Fernández-Novoa · Behavioural Brain Research | 15 Oct 2001 | 94 |
| 18 | Sirtuins in Alzheimer’s Disease: SIRT2-Related GenoPhenotypes and Implications for PharmacoEpiGenetics Ramón Cacabelos, Juan C. Carril, Natalia Cacabelos et al. · International Journal of Molecular Sciences | 12 Mar 2019 | 86 |
| 19 | Epigenetic drug discovery for Alzheimer’s disease Ramón Cacabelos, Clara Torrellas · Expert Opinion on Drug Discovery | 3 Jul 2014 | 85 |
| 20 | Pharmacogenetic Aspects of Therapy with Cholinesterase Inhibitors: The Role of CYP2D6 in Alzheimers Disease Pharmacogenetics Ramón Cacabelos, Ruth Llovo, Carmen Fraile et al. · Current Alzheimer Research | Sep 2007 | 84 |
| 21 | Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions Ramón Cacabelos, Vinogran Naidoo, Lola Corzo et al. · International Journal of Molecular Sciences | 10 Dec 2021 | 83 |
| 22 | TFEB Overexpression in the P301S Model of Tauopathy Mitigates Increased PHF1 Levels and Lipofuscin Puncta and Rescues Memory Deficits Hongjie Wang, Ruizhi Wang, Iván Carrera et al. · eNeuro | May 2016 | 82 |
| 23 | Current Drugs and Potential Future Neuroprotective Compounds for Parkinson’s Disease Iván Carrera, Ramón Cacabelos · Current Neuropharmacology | 27 Nov 2018 | 80 |
| 24 | Pharmacogenomics and therapeutic prospects in dementia Ramón Cacabelos · European Archives of Psychiatry and Clinical Neuroscience | Mar 2008 | 76 |
| 25 | Have there been improvements in Alzheimer’s disease drug discovery over the past 5 years? Ramón Cacabelos · Expert Opinion on Drug Discovery | Apr 2018 | 73 |
| 26 | Citicoline protects hippocampal neurons against apoptosis induced by brain beta-amyloid deposits plus cerebral hypoperfusion in rats X. Anton Alvarez, Carolina Sampedro, Rafael Lozano et al. · Methods and Findings in Experimental and Clinical Pharmacology | 1999 | 73 |
| 27 | Risk Factors and Pathogenesis of HIV-Associated Neurocognitive Disorder: The Role of Host Genetics Ian S. Olivier, Ramón Cacabelos, Vinogran Naidoo · International Journal of Molecular Sciences | 14 Nov 2018 | 72 |
| 28 | Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depression. Ramón Cacabelos · PubMed | Jul 2007 | 71 |
| 29 | Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer’s disease: results of a randomized, double‐blind, controlled trial investigating three dosages of Cerebrolysin X. Anton Alvarez, Ramón Cacabelos, Carolina Sampedro et al. · European Journal of Neurology | 27 May 2010 | 70 |
| 30 | Citicoline improves memory performance in elderly subjects. X. Anton Alvarez, Marta Laredo, Deya Corzo et al. · PubMed | Apr 1997 | 70 |
| 31 | Pharmacological treatment of Alzheimer disease: from psychotropic drugs and cholinesterase inhibitors to pharmacogenomics. R Cacabelos, A Alvarez, Valter Lombardi et al. · PubMed | Jul 2000 | 70 |
| 32 | DNA Methylation in Neurodegenerative and Cerebrovascular Disorders Olaia A. Martínez-Iglesias, Iván Carrera, Juan C. Carril et al. · International Journal of Molecular Sciences | 23 Mar 2020 | 69 |
| 33 | Pharmacoepigenomic Interventions as Novel Potential Treatments for Alzheimer’s and Parkinson’s Diseases Óscar Teijido, Ramón Cacabelos · International Journal of Molecular Sciences | 16 Oct 2018 | 67 |
| 34 | The Application of Functional Genomics to Alzheimer’s Disease Ramón Cacabelos · Pharmacogenomics | Sep 2003 | 67 |
| 35 | Current state of theoretical and experimental studies of the voltage-dependent anion channel (VDAC) Sergei Yu. Noskov, Tatiana K. Rostovtseva, Adam C. Chamberlin et al. · Biochimica et Biophysica Acta (BBA) - Biomembranes | 3 Mar 2016 | 66 |
| 36 | Apolipoprotein E and central nervous system disorders: Reviews of clinical findings Masatoshi Takeda, Rocío Martínez, Takashi Kudo et al. · Psychiatry and Clinical Neurosciences | 25 Nov 2010 | 66 |
| 37 | Combination Treatment in Alzheimers Disease: Results of a Randomized, Controlled Trial with Cerebrolysin and Donepezil X. Anton Alvarez, Ramón Cacabelos, Carolina Sampedro et al. · Current Alzheimer Research | 11 Jul 2011 | 66 |
| 38 | Epigenomic Networking in Drug Development: From Pathogenic Mechanisms to Pharmacogenomics Ramón Cacabelos · Drug Development Research | Sep 2014 | 65 |
| 39 | Pharmacogenomics and therapeutic prospects in Alzheimer’s disease Ramón Cacabelos · Expert Opinion on Pharmacotherapy | Oct 2005 | 63 |
| 40 | Cerebrovascular risk factors in Alzheimer's disease: Brain hemodynamics and pharmacogenomic implications Ramón Cacabelos, Lucía Ferna ́ndez-Novoa, Valter Lombardi et al. · Neurological Research | Sep 2003 | 62 |
| 41 | Link between Cancer and Alzheimer Disease via Oxidative Stress Induced by Nitric Oxide-Dependent Mitochondrial DNA Overproliferation and Deletion Gjumrakch Aliev, Mark E. Obrenovich, Shams S. M. Tabrez et al. · Oxidative Medicine and Cellular Longevity | 2013 | 62 |
| 42 | Pharmacogenomics of Cognitive Dysfunction and Neuropsychiatric Disorders in Dementia Ramón Cacabelos · International Journal of Molecular Sciences | 26 Apr 2020 | 60 |
| 43 | Cerebrolysin® reduces microglial activation in vivo and in vitro: a potential mechanism of neuroprotection X. Anton Álvarez, Valter Lombardi, L. Fernández‐Novoa et al. | 2000 | 59 |
| 44 | Genomics of Dementia:APOE- andCYP2D6-Related Pharmacogenetics Ramón Cacabelos, Rocío Martínez, L. Fernández‐Novoa et al. · International Journal of Alzheimer s Disease | 2012 | 57 |
| 45 | Histamine and Immune Biomarkers in CNS Disorders Ramón Cacabelos, Clara Torrellas, L. Fernández‐Novoa et al. · Mediators of Inflammation | 2016 | 54 |
| 46 | Decreased levels of serum nitric oxide in different forms of dementia Lola Corzo, Raquel Zas, Susana Rodríguez et al. · Neuroscience Letters | 11 May 2007 | 52 |
| 47 | Pharmacogenetic considerations when prescribing cholinesterase inhibitors for the treatment of Alzheimer’s disease Ramón Cacabelos · Expert Opinion on Drug Metabolism & Toxicology | 10 Jun 2020 | 50 |
| 48 | Pharmacogenetic Considerations in the Treatment of Alzheimer’s Disease Ramón Cacabelos, Clara Torrellas, Óscar Teijido et al. · Pharmacogenomics | Jun 2016 | 49 |
| 49 | The apolipoprotein E epsilon 4 allele increases the risk of drug-induced hallucinations in Parkinson's disease. Raúl de la Fuente‐Fernández, Margarita Nunez, E López · PubMed | 28 Sep 1999 | 48 |
| 50 | Neuroimmune Crosstalk in CNS Disorders: The Histamine Connection Ramón Cacabelos, Clara Torrellas, L. Fernández‐Novoa et al. · Current Pharmaceutical Design | 27 Jan 2016 | 48 |
Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.